Mylan and Fujifilm Kyowa Kirin Biologics announced the U.S. Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp), a biosimilar to AbbVie's Humira® (adalimumab).
NHS England said Monday that it negotiated deals with drugmakers on biosimilar versions of AbbVie's Humira (adalimumab), potentially leading to annual savings of 300 million pounds